Retatrutide vs Ozempic: What the Head-to-Head Trial Showed
Eli Lilly released topline results in October 2026 from TRANSCEND-T2D-2, the first Phase 3 trial to compare retatrutide directly against Ozempic 2 mg in adults with type 2 diabetes.1 This page summarises what was reported, what the study could and could not show, and where retatrutide stands in the UK.
Key Takeaways
- Three hormone pathways. Retatrutide acts on the GIP, GLP-1 and glucagon receptors; Ozempic acts on GLP-1 alone.4
- Weight. Average weight loss of 19.5% (9 mg) and 20.9% (12 mg) was reported, against 9.4% on Ozempic 2 mg.1
- Blood glucose. HbA1c fell by 2.2 percentage points on retatrutide and 1.8 on Ozempic 2 mg.1
- Side effects. Mainly gastrointestinal: nausea, diarrhoea, constipation, vomiting and indigestion.3
- UK status. Not licensed, not available outside trials.
Retatrutide is not available in the UK
Retatrutide is an investigational medicine. It has no licence from the MHRA, is not available on prescription, and is being studied in clinical trials only. Ozempic (semaglutide) is a licensed prescription-only medicine, prescribed for its licensed indications after assessment.
Anything sold as retatrutide outside a clinical trial is being supplied illegally in the UK. You cannot rely on its contents, strength or purity. MHRA guidance on buying medicines online8
This page is information about published research. It is not medical advice and not an offer to supply or prescribe any medicine.
What is retatrutide, and how does it differ from Ozempic?
Retatrutide is an investigational once-weekly injectable peptide developed by Eli Lilly. It activates three receptor pathways at once, where the medicines already licensed in this class act on one or two.4
- GLP-1. Reduces appetite, slows gastric emptying and supports insulin release when blood glucose is high.
- GIP. Contributes to glucose regulation by supporting insulin secretion.
- Glucagon. Involved in glucose and energy metabolism; receptor activation is associated with increased energy expenditure.
Retatrutide is being evaluated in Phase 3 trials across obesity and type 2 diabetes, cardiovascular risk factors, knee osteoarthritis and chronic low back pain, obstructive sleep apnoea, and fatty liver disease (MASLD).2
Retatrutide vs Ozempic: comparison
| Feature | Retatrutide | Ozempic |
|---|---|---|
| Drug type | Triple hormone receptor agonist | GLP-1 receptor agonist |
| Mechanism | Targets GIP, GLP-1 and glucagon receptors | Targets GLP-1 receptors |
| Trial dose | 9 mg and 12 mg | 2 mg |
| Administration | Once-weekly injection | Once-weekly injection |
| Average weight loss | 19.5% (9 mg); 20.9% (12 mg) | 9.4% |
| HbA1c reduction | 2.2 percentage points | 1.8 percentage points |
| Common side effects | Nausea, diarrhoea, constipation, vomiting and indigestion | Nausea, diarrhoea, constipation and vomiting |
| Approval status | Investigational; not approved for routine use | Approved medication |
| Availability | Not available as an approved prescription treatment | Available by prescription |
Figures are from an 80-week head-to-head trial in adults with type 2 diabetes and should not be generalised to other patients.1
What did the TRANSCEND-T2D-2 trial find?
TRANSCEND-T2D-2 is a Phase 3, open-label study comparing retatrutide 9 mg and 12 mg against Ozempic 2 mg in adults with type 2 diabetes whose glucose was inadequately controlled on metformin, alone or with an SGLT2 inhibitor. The registry records a planned enrolment of about 1,250 participants over 80 weeks.2
Reported results at 80 weeks
| Measure | Retatrutide 9 mg | Retatrutide 12 mg | Ozempic 2 mg |
|---|---|---|---|
| HbA1c reduction | 2.2 points | 2.2 points | 1.8 points |
| Average weight loss | 19.5% | 20.9% | 9.4% |
| Weight lost | 44.3 lb | 47.4 lb | 20.9 lb |
| Stopped treatment due to side effects | 4.8% | 7.9% | 2.7% |
Source: topline results released by Eli Lilly in October 2026. These are company-reported figures that have not yet been peer reviewed or published in full.1
How reliable are these results?
The 12 mg dose was reported to reduce HbA1c by more than Ozempic 2 mg. The 9 mg dose was reported as comparable rather than superior on that measure.1 Several things limit what can be drawn from this:
- Preliminary. These are topline Phase 3 figures from a company announcement, not a peer-reviewed publication.
- Who was studied. Adults with type 2 diabetes only. The results do not transfer to people without diabetes.
- Open-label. Participants and investigators knew which treatment was given, which can influence reported outcomes.2
- Duration. Eighty weeks says nothing about what happens after treatment stops.
- Not interchangeable. Results from separate trials of different medicines cannot be compared directly with each other.
What has been reported in obesity without diabetes?
TRIUMPH-1 studied retatrutide against placebo in adults with obesity or overweight. The registry records 2,335 participants and a completed study;6 results were subsequently published in the New England Journal of Medicine.5 Reported average weight reductions were dose-dependent: around 25.9% at 9 mg and 28.3% at 12 mg, with a prespecified extension following participants with a baseline BMI of 35 kg/m² or above to 104 weeks.
TRIUMPH-1 compared retatrutide against placebo, not against Ozempic. It is not a comparison between retatrutide and other weight-loss medicines.6
Reported side effects
The adverse events reported in the Phase 3 programme are mainly gastrointestinal, in line with other medicines acting on incretin pathways.7 Those most commonly reported were:
- Nausea — feeling sick.
- Diarrhoea — loose or frequent stools.
- Constipation — difficulty passing stools.
- Vomiting — being sick.
- Dyspepsia — indigestion.
- Cutaneous dysesthesia — unusual skin sensations such as tingling or burning, noted in a subset of participants in the Phase 2 obesity trial, particularly at higher doses.3
- Urinary tract infection.
Most gastrointestinal effects were reported as mild to moderate. In the head-to-head topline, the proportion stopping treatment because of adverse events was higher on retatrutide 12 mg (7.9%) than on Ozempic 2 mg (2.7%).1
Is retatrutide safe?
That question cannot be answered fully for a medicine still under investigation. Most participants in the published Phase 2 trials tolerated it,3 but longer follow-up is needed on liver, cardiovascular and metabolic outcomes before any licensing decision. Unapproved products sold online are a separate and more immediate risk: their ingredients, dose and purity are unknown.8
Retatrutide vs Mounjaro (tirzepatide)
Mounjaro is the brand name for tirzepatide, a licensed medicine used in type 2 diabetes and weight management. Both act on more than one hormone pathway; retatrutide adds a third. You can read more about Mounjaro in Preston.
| Feature | Mounjaro | Retatrutide |
|---|---|---|
| Generic name | Tirzepatide | Retatrutide |
| Hormone targets | GIP and GLP-1 | GIP, GLP-1 and glucagon |
| Main action | Helps regulate appetite and blood sugar | Targets appetite, blood sugar and energy metabolism |
| Treatment status | Approved medicine | Investigational medicine |
| Direct comparison | Being studied in TRIUMPH-5 | Being studied in TRIUMPH-5 |
There is not yet enough comparative data to say which is more effective. Both are being studied in the same Phase 3 trial, TRIUMPH-5. Until it reports, claims that one is superior to the other have no published basis. For context on the licensed options, see weight-loss injections.
Taking part in a retatrutide clinical trial
Trials recruit against specific criteria, and not every study is open at a given time. If you want to look into it:
- Search the register. Retatrutide studies are listed on ClinicalTrials.gov.
- Check the criteria. These usually cover age, BMI, medical history and current treatment.
- Talk to a doctor. Discuss suitability with your GP or an endocrinologist before applying.
- Never pay for a place. Legitimate trials do not charge participants for entry.
Weight management with a GP in Preston
Retatrutide is not a treatment option in the UK. If you want to address weight or metabolic health now, that starts with an assessment rather than a particular medicine. Dr Faizal Secretary provides GP-led medical weight management at My Private Clinic in Fulwood, with unhurried consultations and a plan based on your own health profile. Treatment, where appropriate, is decided after that assessment.
- In person at the Fulwood clinic
- Telephone and video consultations where suitable
- Same-day appointments subject to availability
- Home visits where clinically appropriate
No registration is needed, and you stay with your NHS GP. With your consent we can access your NHS records so your history is taken into account.
Frequently asked questions
Is retatrutide more effective than Ozempic?
In TRANSCEND-T2D-2, the reported reductions in body weight and HbA1c were larger on retatrutide 12 mg than on Ozempic 2 mg among adults with type 2 diabetes. Those figures come from a topline company announcement that has not yet been peer reviewed, and they describe the people enrolled in that study rather than patients in general. Retatrutide is not licensed, so it is not an option in UK practice.
How long does it take for retatrutide to work?
Trial outcomes were measured over 80 weeks, with a prespecified extension to 104 weeks. There is no established timeframe for an individual, and because the medicine is investigational there is no approved dosing schedule for routine care.
How long does retatrutide stay in your system?
It was given as a once-weekly injection in trials. Its elimination time in individuals is not something that can be inferred from the dosing interval, and published data on this is limited.
Does retatrutide cause fatigue?
Fatigue was not among the most frequently reported adverse effects in the published trials. Individual experience varies, and persistent tiredness is worth discussing with a doctor whatever its cause.
Is retatrutide a steroid?
No. Retatrutide is an investigational peptide that acts on hormone receptors involved in metabolism. It is not an anabolic steroid.
Can people with prediabetes take retatrutide?
No. Retatrutide is not licensed for any indication in the UK, including prediabetes. Anyone concerned about blood glucose should discuss assessment and licensed options with a GP.
Is retatrutide the same as Ozempic?
No. Ozempic contains semaglutide and acts on the GLP-1 receptor. Retatrutide acts on three receptors: GIP, GLP-1 and glucagon.
Is retatrutide available over the counter?
No. It is not licensed in the UK and is not available over the counter or on prescription. Anything sold as retatrutide outside a clinical trial is being supplied illegally and its contents, strength and purity cannot be relied on.
Is retatrutide available in the UK?
No. Retatrutide has no UK licence from the MHRA. It is being studied in clinical trials only. Lilly has indicated it is considering regulatory submissions, and any future availability would depend on that process.
References
- Eli Lilly and Company. Retatrutide delivered greater A1C reduction and weight loss than semaglutide 2 mg in adults with type 2 diabetes (TRANSCEND-T2D-2 topline results). October 2026. Company announcement; not peer reviewed. Accessed November 4, 2026. Lilly investor release
- ClinicalTrials.gov. Effect of retatrutide compared with semaglutide in adult participants with type 2 diabetes and inadequate glycaemic control. NCT06260722. Accessed November 4, 2026. NCT06260722
- Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-hormone-receptor agonist retatrutide for obesity — a phase 2 trial. N Engl J Med. 2023;389(6):514-526. doi:10.1056/NEJMoa2301972 N Engl J Med 2023
- Rosenstock J, Frias J, Jastreboff AM, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. Lancet. 2023;402(10401):529-544. doi:10.1016/S0140-6736(23)01053-X Lancet 2023
- Jastreboff AM, Kaplan LM, Davies MJ, et al. Retatrutide, a triple hormone receptor agonist, for treatment of obesity. N Engl J Med. 2026. doi:10.1056/NEJMoa2604169 N Engl J Med 2026
- ClinicalTrials.gov. A study of retatrutide (LY3437943) in participants who have obesity or overweight (TRIUMPH-1). NCT05929066. Accessed November 4, 2026. NCT05929066
- Bajaj HS, Welch M, Shah P, et al. Efficacy and safety of retatrutide in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial. Lancet. 2026;407(10546):2402-2413. doi:10.1016/S0140-6736(26)00967-0 Lancet 2026
- Medicines and Healthcare products Regulatory Agency. Buying medicines online. GOV.UK. Accessed November 4, 2026. MHRA guidance
Trial registry entries and journal records were checked against ClinicalTrials.gov and PubMed on November 4, 2026.